Printer Friendly

Regeneron obtains United States patent.

Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) has patented methods of creating mutations in genomic exons by inserting introns into the genomic exons via homologous recombination. Also, methods are provided for introducing modifications into genomic exons by inserting introns into the genomic exons via homologous recombination such that a mature mRNA transcript produced from a genomic region of the genome comprising the genomic exon does not contain the modification are provided. The methods provide for a rapid method for introducing mutations and/or modifications of any type into a mammalian cell genome. (US 7,205,148)
COPYRIGHT 2007 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:inserting introns into the genomic exons through homologous recombination; Regeneron Pharmaceuticals Inc.
Publication:BIOTECH Patent News
Article Type:Brief article
Date:Apr 1, 2007
Previous Article:Japan Science and Technology Agency obtains United States patent.
Next Article:Genencor obtains United States patent.

Related Articles
A DNA structure that tags genetic junk?
DNA interruptions made a late entrance.
Regeneron And University Of California Receive U.S. Patent Covering Use Of CNTF To Treat Retinal Degeneration.
Regeneron Receives U.S. Patent Covering Gene Encoding Angiopoietin-2, a Natural Antagonist of Angiogenesis.
Akkadix acquires exclusive license to Pangene's enhanced homologous recombination technologies for plant science applications.
Transkaryotic receives patent for gene targeting technology.
Genetic variation in genes associated with arsenic metabolism: glutathione S-transferase omega 1-1 and purine nucleoside phosphorylase polymorphisms...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters